Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

被引：20

作者：

Haug K.B.F. ^{[1
]}

Sharikabad M.N. ^{[1
]}

Kringen M.K. ^{[1
]}

Narum S. ^{[1
]}

Sjaatil S.T. ^{[1
]}

Johansen P.W. ^{[1
]}

Kierulf P. ^{[1
]}

Seljeflot I. ^{[2
]}

Arnesen H. ^{[2
]}

Brørs O. ^{[1
]}

机构：

[1] RandD, Department of Clinical Chemistry, Ulleval University Hospital, O407 Oslo

[2] Center for Clinical Research, Ulleval University Hospital, 0407 Oslo

来源：

Thrombosis Journal | / 6卷 / 1期

关键词：

Warfarin; International Normalize Ratio; Warfarin Dose; Warfarin Treatment; Warfarin Group;

D O I：

10.1186/1477-9560-6-7

中图分类号：

学科分类号：

摘要：

Background: Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WARIS-II study, comparing three different antithrombotic regimens after myocardial infarction, warfarin treatment reduced thrombotic events, but was associated with more frequent bleeding than use of acetylsalisylic acid (ASA) alone. Aims: The primary aim of the present study was to investigate the relation between genotypes of CYP2C9 and VKORC1 and warfarin maintenance dose in myocardial infarction. The secondary aim was to relate the genotypes to international normalized ratio (INR). Methods: Genotyping was performed in 212 myocardial infarction patients from the WARIS-II study by robotic isolation of DNA from EDTA whole blood (MagNa Pure LC) before PCR amplification (LightCycler) and melting point analysis. Results: The 420 C>T substitution of CYP2C9*2, the 1075 A>C substitution of CYP2C9*3 and the 1173 C>T substitution of VKORC1 had minor allele frequencies of, 11.3%, 5.7% and 36.6% respectively. Warfarin weekly dose varied between 17 mg and 74 mg among the patients. INR did not vary between genotypes. Warfarin dosage requirement was significantly associated with CYP2C9 and VKORC1 genotypes, treatment group and age. The VKORC1 genotype contributed 24.5% to the interindividual variation in warfarin dosage, whereas the combined CYP2C9 genotypes were only responsible for 7.2% of the dose variation. Conclusion: CYP2C9 and VKORC1 genotype frequencies in myocardial infarction patients appear similar to other patient groups and have similar impact on warfarin maintenance dose. © 2008 Haug et al; licensee BioMed Central Ltd.

引用

共 32 条

[21]

TIB MOLBIOL

[22]

Basic Local Alignment Search Tool (BLAST)

[23]

Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V., The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement, Thromb Haemost, 95, pp. 782-787, (2006)

[24]

Wadelius M., Pirmohamed M., Pharmacogenetics of warfarin: Current status and future challenges, Pharmacogenomics J, (2006)

[25]

Hillman M.A., Wilke R.A., Caldwell M.D., Berg R.L., Glurich I., Burmester J.K., Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype, Pharmacogenetics, 14, pp. 539-547, (2004)

[26]

Linkins L.A., Choi P.T., Douketis J.D., Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis, Ann Intern Med, 139, pp. 893-900, (2003)

[27]

Osman A., Enstrom C., Arbring K., Soderkvist P., Lindahl T.L., Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: A retrospective analysis of case records, J Thromb Haemost, 4, pp. 1723-1729, (2006)

[28]

Sanderson S., Emery J., Higgins J., CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis, Genet Med, 7, pp. 97-104, (2005)

[29]

Odegaard K.J., Self-management in anticoagulation - A meta-analysis, Tidsskr Nor Laegeforen, 124, pp. 2900-2903, (2004)

[30]

Yasar U., Bennet A.M., Eliasson E., Lundgren S., Wiman B., De Faire U., Rane A., Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction, Pharmacogenetics, 13, pp. 715-720, (2003)

← 1 2 3 4 →